cylembio
·Code: IO102-IO103, IOB-013/KN-D18
cylembio: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IO Biotech, Inc. (IOBT) | Phase 2 |
FDA Decisions
FDA_MeetingFDA recommended that the Company not submit a BLA based on the data from the IOB-013 clinical trial.(IOBT)
Frequently asked questions
Who is developing cylembio?
cylembio is being developed by IO Biotech, Inc..
What is cylembio's latest FDA decision?
The most recent tracked FDA decision for cylembio is FDA_Meeting for FDA recommended that the Company not submit a BLA based on the data from the IOB-013 clinical trial..
Get deeper analysis on cylembio
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis